Tysabri Progressive Multifocal Leukoencephalopathy Attorney: New York Tysabri PML Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science communication has served as a foundational pillar for public understanding, offering accessible guidance on wellness, disease prevention, and the safe use of medical therapies. This legacy of broad, evidence-informed information has empowered individuals to make informed decisions about their care, particularly when navigating complex treatment landscapes. Within this tradition, the focus has often remained on the benefits and risks of pharmaceutical interventions in a clinical setting, emphasizing patient education and shared decision-making. As this informational framework evolves, it becomes necessary to address specific, real-world consequences that arise from therapeutic exposure. One such area of concern involves the use of immunomodulatory medications, where the balance between therapeutic efficacy and adverse outcomes demands careful scrutiny. In particular, the administration of certain biologic agents has been associated with an elevated risk of opportunistic infections, including conditions that affect the central nervous system. This shift from general health awareness to targeted risk assessment is critical for individuals who have undergone such treatments.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

The transition from a broad health context to a focused occupational and legal concern is now clear. For those who have received Tysabri therapy and subsequently developed Progressive Multifocal Leukoencephalopathy (PML), the implications extend beyond clinical management into questions of liability and compensation. Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of PML, a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, highlighting this risk and mandating that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML. Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Clinical Evidence for Tysabri-Associated PML

Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these patients had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a severe demyelinating disease caused by JC polyomavirus (JCV), affecting immunocompromised individuals. A retrospective national cohort study of Italian PML patients observed between 1987 and 2024, including 456 cases with either a definite or clinico-radiological diagnosis, described changing clinical and laboratory characteristics of PML over time and according to underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/). This study underscores the importance of early recognition and diagnosis of PML in patients receiving immunosuppressive therapies like Tysabri.

Legal Considerations for Tysabri PML Patients in New York

In New York, individuals affected by this serious neurological condition may seek the counsel of a specialized attorney to navigate the complexities of injury claims, ensuring that their exposure history is properly evaluated within the legal framework. The clinical presentation of PML can be variable, often including progressive neurological deficits such as weakness, cognitive impairment, visual disturbances, and speech difficulties. Diagnosis typically involves brain imaging (MRI) showing demyelinating lesions, detection of JCV DNA in cerebrospinal fluid, and sometimes brain biopsy. The FDA boxed warning emphasizes that healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a critical consideration. The FDA has mandated a boxed warning and a restricted distribution program, but questions may arise about whether patients and healthcare providers fully understand the magnitude of risk, especially in the context of long-term therapy. The timeline between exposure to Tysabri and documented harm is variable; PML can occur after months to years of treatment, with risk increasing with longer duration, particularly beyond 2 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency can complicate attribution of harm to the drug, especially if other risk factors are present. For affected patients and their families, attorney-related considerations may include evaluating whether the risks of PML were adequately communicated before treatment initiation. Patients who develop PML after Tysabri therapy may face severe disability or death, and legal claims could focus on failure to warn, inadequate monitoring, or failure to promptly withhold treatment upon symptom onset. The FDA's boxed warning and the TOUCH program provide a framework for risk mitigation, but adherence to these protocols by healthcare providers is essential. Patients should be aware of the symptoms of PML and the importance of immediate medical evaluation if any new neurological symptoms arise.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It is associated with an increased risk of Progressive Multifocal Leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors increase the likelihood of PML: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How can a New York attorney help if I developed PML after Tysabri?

A specialized attorney can evaluate whether the risks of PML were adequately communicated, whether monitoring was appropriate, and whether there was a failure to promptly withhold treatment upon symptom onset. They can help pursue claims for compensation related to severe disability or death caused by PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.